Promoting apoptosis as a strategy for cancer drug discovery
SW Fesik - Nature Reviews Cancer, 2005 - nature.com
Nature Reviews Cancer, 2005•nature.com
Apoptosis is deregulated in many cancers, making it difficult to kill tumours. Drugs that
restore the normal apoptotic pathways have the potential for effectively treating cancers that
depend on aberrations of the apoptotic pathway to stay alive. Apoptosis targets that are
currently being explored for cancer drug discovery include the tumour-necrosis factor (TNF)-
related apoptosis-inducing ligand (TRAIL) receptors, the BCL2 family of anti-apoptotic
proteins, inhibitor of apoptosis (IAP) proteins and MDM2.
restore the normal apoptotic pathways have the potential for effectively treating cancers that
depend on aberrations of the apoptotic pathway to stay alive. Apoptosis targets that are
currently being explored for cancer drug discovery include the tumour-necrosis factor (TNF)-
related apoptosis-inducing ligand (TRAIL) receptors, the BCL2 family of anti-apoptotic
proteins, inhibitor of apoptosis (IAP) proteins and MDM2.
Abstract
Apoptosis is deregulated in many cancers, making it difficult to kill tumours. Drugs that restore the normal apoptotic pathways have the potential for effectively treating cancers that depend on aberrations of the apoptotic pathway to stay alive. Apoptosis targets that are currently being explored for cancer drug discovery include the tumour-necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) receptors, the BCL2 family of anti-apoptotic proteins, inhibitor of apoptosis (IAP) proteins and MDM2.
nature.com